Skip to main content

Advertisement

Log in

Health economic issues of screening programmes

  • Article
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Economic evaluation supports decision making in health care in view of alternative courses of action and limited resources. It aims at providing maximum benefit in relation to invested resources. In the context of screening, it is required from an economical viewpoint that the cost of case finding, including confirmatory diagnostic tests and treatment, should be economically balanced in relation to possible expenditure on medical care as a whole. Costs of false-positive findings are crucial in newborn screening and pertain to direct costs (e.g. necessary diagnostic work-up), indirect costs (e.g. absence from work of parents) and intangible costs (e.g. anxiety and distress caused, stigmatisation).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

CBA :

cost-benefit analyses

CEA :

cost-effectiveness analyses

CMA :

cost-minimisation analyses

COI :

cost-of-illness studies

PKU :

phenylketonuria

QALY :

quality-adjusted life years

References

  1. Banta HD, Luce BR (1993) Health care technology and its assessment. An international perspective. Oxford University Press, Oxford

  2. Drummond MF, Stoddart GL, Torrance GW (1998) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford

  3. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York

  4. Insinga RP, Laessig RH, Hoffman GL (2002) Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr 141: 524–531

    Article  PubMed  Google Scholar 

  5. Lord J, Thomason MJ, Littlejohns P, Chalmers RA, Bain MD, Addison GM, Wilcox AH, Seymour CA (1999) Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. J Epidemiol Community Health 53: 179–186

    CAS  PubMed  Google Scholar 

  6. Murray CJL, Lopez AD (1996) The global burden of disease. World Health Organization, Geneva

  7. Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, Nicholl J, Nicholson P, Tunaley JR, Virdi NK (1997) Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technology Assessment 1: 1–202

    Google Scholar 

  8. Schoen EJ, Baker JC, Colby CJ, To TT (2002) Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 110: 781–786

    PubMed  Google Scholar 

  9. WHO (2000) The World Health Report 2000. Health systems: improving performance. World Health Organization, Geneva

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Manfred Wildner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wildner, M. Health economic issues of screening programmes. Eur J Pediatr 162 (Suppl 1), S5–S7 (2003). https://doi.org/10.1007/s00431-003-1341-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-003-1341-5

Keywords

Navigation